Newly developed drugs invented to treat tuberculosis in clinical trial

doi:10.5246/jcps.2017.01.001

Abstract

Abstract:

Tuberculosis (TB) is a leading cause of morbidity and mortality in more than one-third of the world population. Its impact on global health is a result of decades of neglect for such an important infectious disease, lack of resources for national TB control programs, poor case detection, and inadequate/inappropriate therapy in high-burden countries. The worldwide dissemination of multidrug (MDR) and extensively drug resistant (XDR) Mycobacterium tuberculosis poses a serious threat to human health due to inadequacy of long and cumbersome tuberculosis (TB) therapy. Treatment regimens consist of at least four drugs with different mechanisms of action. Several new molecules in clinical development hasencouraged the scientific community to discover new drug targets and new drug candidates. Therefore, new drugs are urgently needed to shorten and improve the treatment course in drug resistant TB, and to minimize the occurrence of new infections and death. Nowadays, various new investigational drugs, such as bedaquine (TMC207), nitroimidazoles (PA-824, OPC-67683), diamines (SQ109), oxazolidinones (Linezolid, PNU-100480 (Sutezolid), ADZ5847), pyrroles (LL3858) and fluoroquinolones (moxifloxacin and gatifloxacin), have entered clinical trials and are in progress to be developed for the treatment of MDR-TB. In this perspectivearticle, an overview of the new anti-TB drugs with different structures that are either being clinically used or in advanced stages clinical stages as well as of preclinical development are presented. This review provides snapshots of the efforts that are being made in the development of new drugs as lead anti-TB agents. Finally, it is crucial to improve the connection between research and development institutes, industries, drug control authorities, and international policy-making bodies to deliver efficacious therapies for patients who are suffering from TB.

Key words: Tuberculosis, Mycobacterium tuberculosis, Multidrug resistance, Extensively drug resistance, Treatment, New targets, Challenges

CLC Number:

R916

Supporting:

Mohammad Asif. Newly developed drugs invented to treat tuberculosis in clinical trial[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(1): 1-22.

References

[1] World Health Organization (WHO). Global Tuberculosis Report 2012; WHO Press, World Health Organization: Geneva, Switzerland, 2012.
[2] Zhang, Y.; Post-Martens, K.; Denkin, S. Drug Discov. Today. 2006, 11, 21-27.
[3] Pham, T.; Nguyen, T.; Nguyen, L. J. Anc. Dis. Prev. Rem. 2013, 1, 1-2.
[4] World Health Organization (WHO). The use of bedaquiline in the treatment of multidrug-resistant tuberculosis, Interim Policy Guidance. WHO Press, World Health Organization: Geneva, Switzerland, 2013.
[5] Anishetty, S.; Pulimi, M.; Pennathur, G. Comput. Biol. Chem. 2005, 29, 368-378.
[6] Ahmad, S.; Mokaddas, E. Respiratory. Medicine. CME. 2010, 3, 51-56.
[7] World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency Update 2008. WHO Press, World Health Organization: Geneva, Switzerland, 2008.
[8] World Health Organization (WHO). Treatment of Tuberculosis Guidelines.Fourth Edition. WHO Press, World Health Organization: Geneva, Switzerland, 2010.
[9] Orenstein, E.W.; Basu, S.; Shah, S. Lancet. Infect. Dis. 2009, 9, 153-161.
[10] American Thoracic Society, CDC, and Infectious Disease Society of America. Treatment of tuberculosis. MMWR. 2003, 52, 1-77.
[11] Conde, M.B.; Silva, J.R.L. Drug Dev. Res. 2011, 72, 501-508.
[12] Dover, L.G.; Coxon, G.D. J. Med. Chem. 2011, 54, 6157-6165.
[13] Wright, A.; Bai, G.; Barrera, L.; Boulahbal, F.; Martín-Casabona, N.; Gilpin, C.; Drobniewski, F.; Havelkova, M.; Lepe, R.; Lumb, R.; Metchock, B.; Portaels, F.; Rodrigues, M.; Rusch-Gerdes, S.; Van Deun, A.; Vincent, V.; Leimane, V.; Riekstina, V.; Skenders, G.; Holtz, T.; Pratt, R.; Laserson, K.; Wells, C.; Cegielski, P.; Shah, N.S. Morbidity Mortality Wkly Rep. 2006, 55, 301-305.
[14] WHO Global Task Force Outlines Measures to Combat XDRTB Worldwide. http//www.who.int/mediacentre/news/notes/2006 np29/en/index.html
[15] Mario, C.; Raviglione, M.D. N. Engl. J. Med. 2008, 359, 6.
[16] Velayati, A.A.; Masjedi, M.R.; Farnia, P.; Tabarsi, P.; Ghanavi, J.; Ziazarifi, A.H.; Hoffner, S.E. Chest. 2009, 136, 420-425.
[17] Rowland, K. Nature. 2012, 13.
[18] Udwadia, Z.F.; Amale, R.A.; Ajbani, K.K.; Rodrigues, C. Clin. Infect. Dis. 2011, 54, 579-581.
[19] Harries, A.D.; Zachariah, R.; Corbett, E.L. Lancet. 2010, 375, 1906-1919.
[20] Toossi, Z.; Xia, L.; Wu, M.; Salvekar, A. Clin. Exp. Immunol. 1999, 117, 324-330.
[21] Boulle, A.; Van-Cutsem, G.; Cohen, K. J. Am. Med. Assoc. 2008, 300, 530-539.
[22] Manosuthi, W.; Sungkanuparph, S.; Tantanathip, P. Clin. Infect. Dis. 2009, 48, 1752-1759.
[23] L’homme, R.F.; Nijland, H.M.; Gras, L. Aids. 2009, 27, 863-865.
[24] Nijland, H.M.; L’homme, R.F.; Rongen, G.A. Aids. 2008, 22, 931-935.
[25] Blanc, F.X.; Sok, T.; Laureillard, D. N. Engl. J. Med. 2011, 365, 1471-1481.
[26] Karim, S.A.; Naidoo, N.P.; Grobler, A. N. Engl. J. Med. 2011, 365, 1492-1501.
[27] Havlir, D.V.; Kendall, M.A.; Ive, P. N. Engl. J. Med. 2011, 365, 1482-1491.
[28] Leach, K.L.; Brickner, S.J.; Noe, M.C.; Miller, P.F.; Ann, N.Y. Acad. Sci. 2011, 1222, 49-54.
[29] Zhang, Y.; Post-Martens, K.; Denkin, S. Drug. Discov. Today. 2006, 11, 21-27.
[30] Williams, K.N.; Stover, C.K.; Zhu, T.; Tasneen, R.; Tyagi, S.; Grosset, J.H.; Nuermberger, E. Antimicrob. Agents.Chemother. 2009, 1314-1319.
[31] Dietze, R.; Hadad, D.J.; Mc Gee, B. Am. J. Respir. Crit. Care. Med. 2008, 178, 1180-1185.
[32] Khasawneh, F.A.; Moti, D.F.; Zorek, J.A. J. Medical. Case. Reports. 2013, 7, 46.
[33] Jones, D. Nature Rev. 2013, 3, 12.
[34] Williams, K.N.; Stover, C.K.; Zhu, T. Antimicrob. Agents Chemother. 2009, 53, 1314-1319.
[35] Alffenaar, J.W.C.; van-der Laan, T.; Simons, S.; van-der Werf, T.S.; van-de Kasteele, P.J.; de Neeling, H.; Soolingen, D.V. Antimicrob. Agents. Chemother. 2011, 55, 1287-1289.
[36] Wallis, R.S.; Jakubiec, W.M.; Kumar, V.; Silvia, A.M.; Paige, D.; Dimitrova, D.; Li, X.; Ladutko, L.; Campbell, S.; Friedland, M.G.; Miller, P.F. J. Infect. Dis. 2009, 202, 745-751.
[37] Reele, S.; Xiao, A.J.; Das, S. Antimicrob. Agents Chemother. 2011, 17-20.
[38] Xiao, A.J.; Das, S.; Reele, S. Antimicrob. Agents Chemother. 2011, 17-20.
[39] Matsumoto, M.; Hashizume, H.; Tomishige, T. PLoS Med. 2006, 3, 466.
[40] Zhang, Q.; Liu, Y.; Tang, S.; Sha, W.; Xiao, H. Cell Biochem. Biophys. 2013, 67, 957-963.
[41] Choi, K.P.; Bair, T.B.; Bae, Y.M.; Daniels, L. J. Bacteriol. 2001, 183, 7058-7066.
[42] Singh, R.; Manjunatha, U.; Boshoff, H. Science. 2008, 322, 1392-1395.
[43] Manjunatha, U.; Boshoff, H.I.M.; Barry, C.E. Comm. Integr. Biol. 2009, 2, 215-218.
[44] Lenaerts, A.J.; Gruppo, V.; Marietta, K.S.; Johnson, C.M.; Driscoll, D.K.; Tompkins, N.M.; Rose, J.D.; Reynolds, R.C.; Orme, I.M. Antimicrob. Agents. Chemother. 2005, 49, 2294-2301.
[45] Nuermberger, E.; Tyagi, S.; Tasneen, R.; Williams, K.N.; Almeida, D.; Rosenthal, I.; Grosset, J.H. Antimicrob. Agents. Chemother. 2008, 52, 1522-1524.
[46] Richard, H. (National Institute of Allergy and Infectious Diseases, Bethesda, MD). E-mail with: Erica Lessem (Treatment Action Group, New York, NY), June 4, 2012.
[47] Andries, K.; Verhasselt, P.; Guillemont, J. Science. 2005, 307, 223-227.
[48] Lounis, N.; Veziris, N.; Chauffour, A. Antimicrob. Agents. Chemother. 2006, 50, 3543-3547.
[49] Lessem, E.; McKenna, L. An Activist’s Guide to Bedaquiline (Sirturo). Treatment Action Group. February 2013.
[50] Gaurrand, S.; Desjardins, S.; Meyer, C. Biol. Drug. Des. 2006, 68, 77-84.
[51] Mahajan, R. Int. J. App. Basic. Med. Res. 2013, 3, 1-2.
[52] Matteelli, A.; Carvalho, A.C.C.; Dooley, K.E. Future Microbiol. 2010, 5, 849-858.
[53] Rustomjee, R.; Diacon, A.H.; Allen, J. Agents. Chemother. 2008, 52, 2831-2835.
[54] Diacon, A.H.; Pym, A.; Grobudch, M. N. Engl. J. Med. 2009, 360, 2397-2405.
[55] Diacon, A.H.; Donald, P.R.; Pym, A. Agents. Chemother. 2012, 56, 3271-3276.
[56] Okumura, R.; Hirata, T.; Onodera, Y.; Hoshino, K.; Otani, T.; Yamamoto, T. J. Antimicrob. Chemother. 2008, 62, 98-104.
[57] Hoshino, K.; Inoue, K.; Murakami, Y.; Kurosaka, Y.; Namba, K.; Kashimoto, Y.; Uoyama, S.; Okumura, R.; Higuchi, S.; Otani, T. Antimicrob. Agents. Chemother. 2008, 52, 65-76.
[58] Disratthakit, A.; Doi, N. Antimicrob. Agents. Chemother. 2010, 54, 2684-2686.
[59] Ahmad, Z.; Minkowski, A.; Peloquin Williams, K.N.; Mdluli, K.E.; Grosset, J.H.; Nuermberger, E.L. Antimicrob. Agents. Chemother. 2011, 1781-1783.
[60] Hotoda, H.; Furukawa, M.; Daigo, M.; Murayama, K.; Kaneko, M.; Muramatsu, Y.; Ishii, M.M.; Miyakoshi, S.; Takatsu, T.; Inukai, M.; Kakuta, M.; Abe, T.; Harasaki, T.; Fukuoka, T.; Utsui, Y.; Ohya, S. Bioorg. Med. Chem. Lett. 2003, 13, 2829-2832.
[61] Nikonenko, B.V.; Protopopova, M.; Samala, R.; Einck, L.; Nacy, C.A. Antimicrob. Agents. Chemother. 2007, 51, 1563-1565.
[62] Tahlan, K.; Wilson, R.; Kastrinsky, D.B.; Arora, K.; Nair, V.; Fischer, E.; Barnes, S.W.; Walker, J.R.; Alland, D.; Barry, III C.E.; Boshoff, H.I. Antimicrob. Agents. Chemother. 2012, 56, 1797-1809.
[63] Protopopova, M.; Hanrahan, C.; Nikonenko, B.; Samala, R.; Chen, P.; Gearhart, J.; Einck, L.; Nacy, C.A. J. Antimicrob. Chemother. 2005, 56, 968-974.
[64] Kimura, K.I.; Bugg, T.D.H. Nat. Prod. Rep. 2003, 20, 252-273.
[65] Bugg, T.D.; Lloyd, A.J.; Roper, D.I. Infect. Disord. Drug. Targets. 2006, 6, 85-106.
[66] Nikonenko, B.V.; Reddy, V.M.; Protopopova, M.; Bogatcheva, E.; Einck, L.; Nacy, C.A. Antimicrob. Agents. Chemother. 2009, 53, 3138-3139.
[67] Reddy, V.M.; Einck, L.; Nacy, C.A. Antimicrob. Agents. Chemother. 2008, 52, 719-721.
[68] Arora, S. Int. J. Tuberc. Lung. Dis. 2004, 8, S29.
[69] Arora, S.K.; Sinha, N.; Jain, A. Patent WO200426828, 2004.
[70] Arora, S.K.; Sinha, N.; Sinha, R.; Upadhayaya, R.S. Patent US20050256128, 2005.
[71] Cardona, P.J. Rijeka: InTech, 2012, 560.
[72] Lechartier, B.; Hartkoorn, R.C.; Cole, S.T. Antimicrob. Agents. Chemother. 2012, 56, 5790.
[73] Karoli, T.; Becker, B.; Zuegg, J.; Mollmann, U.; Ramu, S.; Huang, J.X.; Cooper, M.A. J. Med. Chem. 2012, 55, 7940-7944.
[74] Batt, S.M.; Jabeen, T.; Bhowruth, V.; Quill, L.; Lund, P.A.; Eggeling, L.; Alderwick, L.J.; Fütterer, K.; Besra, G.S. 2012, 109, 11354-11359.
[75] Makarov, V.; Manina, G.; Mikusova, K. Science. 2009, 324, 801-804.
[76] Brodin, P.; Christophe, T. Curr. Opin. Chem. Biol. 2011, 15, 534-539.
[77] Makarov, V.; Neres, J.; Hartkoorn, R.C.; Ryabova, O.B.; Kazakova, E.; Šarkan, M.; Huszár, S.; Piton, J.; Kolly, G.S.; Vocat, A.; Conroy, T.M.; Mikušová, K.; Cole, S.T. Antimicrob. Agents Chemother. 2015, 9, 4446-4452.
[78] Carette, X.; Blondiaux, N.; Willery, E. Nucl. Acids. Res. 2011, 1-13.
[79] Willand, N.; Dirie, B.; Carette, X.; Bifani, P.; Singhal, A.; Desroses, M.; Leroux, F.; Willery, E.; Mathys, V.; De’prez-Poulain, R.; Delcroix, G.; Frenois, F.; Aumercier, M.; Locht, C.; Villeret, V.; Deprez, B.; Baular, A.R. Nat. Med. 2009, 15, 537-544.
[80] Engohang-Ndong, J.; Baillat, D.; Aumercier, M.; Bellefontaine, F.; Besra, G. S.; Locht, C.; Baulard, A.R. Mol. Micro. Boil. 2004, 51, 175-188.
[81] Bogatcheva, E.; Hanrahan, C.; Nikonenko, B.; de los Santos, G.; Reddy, V.; Chen, P.; Barbosa, F.; Einck, L.; Nacy, C.; Protopopova, M. Bioorg. Med. Chem. Lett. 2011, 21, 5353-5357.
[82] Arora, S. Int. J. Tuberc. Lung. Dis. 2004, 8, S29.
[83] Arora, S.K.; Sinha, N.; Jain, A. Patent WO200426828, 2004.
[84] Arora, S.K.; Sinha, N.; Sinha, R.; Upadhayaya, R.S. Patent US20050256128, 2005.
[85] Cardona, P.J. editor. Rijeka: InTech. 2012, 1-46.
[86] Iseman, M.D. Eur Respir J. 2002, 36, S87-94.
[87] Manika, K.; Kioumis, I. 2008, 21, 395-401.
[88] Gosling, R.D.; Uiso, L.O.; Sam, N.E. Am. J. Respir. Crit. Care. Med. 2003, 168, 1342-1345.
[89] Von Keutz, E.; Schluter, G. J. Antimicrob Chemother. 1999, 43, 91-100.
[90] Johnson, J.L.; Hadad, D.J.; Boom, W.H. Int. J. Tuberc. Lung Dis. 2006, 10, 605-612.
[91] Nuermberger, E.L.; Yoshimatsu, T.; Tyagi, S. Am. J. Respir. Crit. Care. Med. 2004, 169, 421-426.
[92] Burman, W.J.; Goldberg, S.; Johnson, J.L. Am. J. Respir. Crit. Care. Med. 2006, 174, 331-338.
[93] Alvirez-Freites, E.J.; Carter, J.L.; Cynamon. M.H. Antimicrob. Agents. Chemother. 2002, 46, 1022-1025.
[94] Kratky, M.; Vinsova, J. Curr. Med. Chem. 2012, 19, 6126-6137.
[95] Dunn, M.F.; Trujillo, J.A.R.; Hernandez-Lucas, I. Microbiology. 2009, 3166-3175.
[96] Reddy, V.M.; O’Sullivan, J.F.; Gangadharam, P.R.J. J. Antimicrob. Chemother. 1999, 43, 615-623.
[97] Field, S.K.; Cowie, R.L. Chest. 2003, 124, 1482-1786.
[98] Reddy, V.M.; Srinivasan, S.; Gangadharam, P.R. Tuber. Lung. Dis. 1994, 75, 208-212.
[99] Reddy, V.M.; Nadadhur, G.; Daneluzzi, D.; O’Sullivan, J.F.; Gangadharam, P.R. Antimicrob. Agents, Chemother. 1996, 40, 633-636.
[100] Liu, B.; Liu, K.; Lu, Y.; Zhang, D.; Yang, T.; Li, X.; Ma, C.; Zheng, M.; Wang, B.; Zhang, G.; Wang, F.; Ma, Z.; Li, C.; Huang, H.; Yin, D. Molecules. 2012, 17, 4545-4559.
[101] Barry, V.C.; Belten, J.G.; Cnalty, M.L.; Denneny, J.M.; Edward, D.W.; O’Sullivan, J,F. Nature. 1957, 179, 1013-1015.
[102] Morrission, N.E.; Marley, G.M. Int. J. Lepr. 1957, 44, 133-134.
[103] Zhang, D.; Lu, Y.; Liu, K. J. Med. Chem. 2012, 55, 8409−8417.
[104] De Lorenzo, S.; Alffenaar, J.W.; Sotgiu, G. Eur. Respir. J. 2013, 41, 1386-1392.
[105] Alsaad, N.; Wilffert, B.; van Altena, R. Eur. Respir. J. 2014, 43, 884-897.
[106] Alsaad, N.; van Altena, R.; Pranger, A.D. Eur. Respir. J. 2013, 42, 504-512.
[107] Jawahar, M.S.; Banurekha, V.V.; Paramasivan, C.N. PLoS One. 2013, 8, e67030.
[108] Merle, C.S.; Fielding, K.; Sow, O.B. N. Engl. J. Med. 2014, 371, 1588-1598.
[109] Merle, C.S.; Sismanidis, C.; Sow, O.B. Trials. 2012, 13, 61.
[110] Smythe, W.; Merle, C.S.; Rustomjee, R. Antimicrob. Agents. Chemother. 2013, 57, 4164-4171.
[111] Dawson, R.; Diacon, A.H.; Everitt, D. Lancet. 2015, 385, 1738-1747.
[112] Sotgiu, G.; Migliori, G.B. Eur. Respir. J. 2015, 45, 25-29.
[113] Falzon, D.; Jaramillo, E.; Schünemann, H.J. Eur. Respir. J. 2011, 38, 516-528.
[114] World Health Organization.WHO Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva, World Health Organization. 2014.
[115] Dara M, Kluge H. Roadmap to prevent and combat drug-resistant tuberculosis. Copenhagen, World Health Organization Regional Office for Europe. 2011. www.euro.who.int/__data/assets/pdf_file/0014/152015/ e95786.pdf
[116] Heysell, S.K.; Moore, J.L.; Keller, S.J. Emerging. Infect. Dis. 2010, 16, 1546-1553.
[117] Peloquin, C.A.; Ann, N.Y. Acad. Sci. 2001, 953, 157-164.
[118] Peloquin, C.A. Drugs. 2002, 62, 2169-2183.
[119] Migliori, G.B.; Sotgiu, G.; D’Ambrosio, L. Eur. Respir. J. 2012, 39, 619-625.
[120] Raviglione, M.C.; Lange, C.; Migliori, G.B. Eur. Respir. J. 2011, 37, 978-981.
[121] Van der Werf, M.J.; Langendam, M.W.; Huitric, E. Eur. Respir. J. 2012, 39, 1511-1519.
[122] Srivastava, S.; Pasipanodya, J.G.; Meek, C. J. Infect. Dis. 2011, 204, 1951-1959.
[123] Sotgiu, G.; Centis, R.; D’Ambrosio, L. Eur. Respir. J. 2012, 40, 1430-1442.
[124] Srivastava, S.; Peloquin, C.A.; Sotgiu, G. Eur. Respir. J. 2013, 42, 1449-1453.
[125] Vu, D.H.; Alffenaar, J.W.C.; Edelbroek, P.M. Curr. Pharm. Des. 2011, 17, 2931-2939.
[126] Migliori, G.B.; Zellweger, J.P.; Abubakar, I. Eur. Respir. J. 2012, 39, 807-819.
[127] van der Werf, M.J.; Sandgren, A.; D’Ambrosio, L. Eur. Respir. J. 2014, 43, 933-942.
[128] World Health Organization.Framework for tuberculosis elimination in low-incidence countries. Document WHO/HTM/TB/2014.13. Geneva, World Health Organization. 2014.
[129] Diel, R.; Loddenkemper, R.; Zellweger, J.P. Eur. Respir. J. 2013, 42, 785-801.
[130] D’Ambrosio, L.; Dara, M.; Tadolini, M. Eur. Respir. J. 2014, 43, 1410-1420.
[131] Voniatis, C.; Migliori, G.B.; Voniatis, M. Eur. Respir. J. 2014, 44, 543-546.
[132] Blasi, F.; Barnes, P.J.; Gaga, M. Eur. Respir. J. 2013, 42, 875-880.
[133] Blasi, F.; Reichman, L.B.; Migliori, G.B. Eur. Respir. J. 2012, 40, 806-808.
[134] Esposito, S.; D’Ambrosio, L.; Tadolini, M. Eur. Respir. J. 2014, 44, 811-815.
[135] Codecasa, L.R.; Ciconali, G.; Mazzola, E. Eur. Respir. J. 2015, 45, 25-29.
[136] D’Ambrosio, L.; Tadolini, M.; Dupasquier, S. Eur. Respir. J. 2014, 43, 286-289.
[137] Janssen, S.; Jayachandran, R.; Khathi, L. Drug Design, Development & Therapy. 2012, 6, 217-224.
[138] Kinnings, S.L.; Liu, N.; Buchmeier, N. PLoSComput Biol. 2009, 5, 1-10.
[139] Mor, A. Drug. Dev. Res. 2000, 50, 440-447.
[140] McDermott, W. Yale. J. Biol. Med. 1958, 30, 257-291.
[141] McKinney, J.D.; HönerzuBentrup, K.; Muñoz-Elías, E.J. Nature. 2000, 406, 735-738.
[142] Glickman, M.S.; Cox, J.S.; Jacobs, W.R. Mol. Cell. 2000, 5, 717-727.
[143] Dahl, J.L.; Kraus, C.N.; Boshoff, H.I.M. Proc. Natl. Acad. Sci. 2003, 100, 10026-10031.
[144] Park, H.D.; Guinn, K.M.; Harrell, M.I. Mol. Microbiol. 2003, 48, 833-843.
[145] Zhang, Y.; Wade, M.M.; Scorpio, A. J. Antimicrob. Chemother. 2003, 52, 790-795.
[146] Engelberg-Kulka, H.; Sat, B.; Reches, M. Trends Microbiol. 2004, 12,66-71.
[147] Gerdes, K.; Christensen, S.K.; Løbner-Olesen, A. Nat. Rev. Microbiol. 2005, 3, 371-382.
[148] Sassetti, C.M.; Boyd, D.H.; Rubin, E.J. Mol. Microbiol. 2003, 48, 77-84.
[149] Sassetti, C.M.; Rubin, E. J. Proc. Natl. Acad. Sci. USA. 2003, 100, 12989-12994.
[150] Ollinger, J.; O'Malley, T.; Kesicki, E.A. J. Bacteriol. 2012, 194, 663-668.
[151] Sacks, L.V.; Behrman, R.E. Tuberculosis. 2008, 88, S93-S100.
[152] Casenghi, M.; Cole, S.T.; Nathan, C.F. PLoS Med, 2007, 4, 1722-1725.
[153] Boogaard, J.; Kibiki, G.S.; Kisanga, E.R. Antimicrob. Agents. Chemother. 2009, 53, 849-862.
[154] Zhang, Y. Front. Biosci. 2004, 9, 1136-1156.
[155] Tomioka, H.; Namba, K. Kekkaku. 2006, 81, 753-774.
[156] Ginsberg, A.M.; Spigelman, M. Nature Medicine. 2007, 13, 290-294.
[157] Pandey, R.; Khuller, G.K. J. Antimicrob. Chemother. 2004, 54, 266-268.
[158] Gelperina, S.; Kisich, K.; Iseman, M.D. Am. J. Respir. Crit. Care. Med. 2005, 172, 1487-1490.
[159] Pandey, R.; Zahoor, A.; Sharma, S. Tuberculosis. 2003, 83, 373-378.
[160] Nuermberger, E.L.; Spigelman, M.K.; Yew, W.W. Respirology. 2010, 15, 764-778.
[161] Anisimova, Y.V.; Gelperina, S.; Peloquin, C. J. Nanoparticle. Res. 2000, 2, 165-171.
[162] Barrow, E.L.; Winchester, G.A.; Staas, J.K. Antimicrob. Agents Chemother. 1998, 42, 2682-2689.
[163] Fawaz, F.; Bonini, F.; Maugein, J. Int. J. Pharm, 1998, 168, 255-259.
[164] Grosset, J. Antimicrob. Agents. Chemother. 2003, 47, 833-836.
[165] Pandey, R.; Khuller, G.K. J. Antimicrob. Chemother. 2005, 55, 430-435.
[166] Fiegel, J.; Garcia-Contreras, L.; Thomas, M. Pharm. Res. 2008, 25, 805-811.
[167] Garcia-Contreras, L.; Sung, J.C.; Muttil, P. Antimicrob. Agents. Chemother. 2010, 54, 1436-1442.
[168] Garcia-Contreras, L.; Fiegel, J.; Telko, M.J. Antimicrob. Agents. Chemother. 2007, 51, 2830-2836.
[169] Asif, M. Orien.Pharm. Experi. Med. 2012, 12, 15-34.
[170] Asif, M. Indian. Drugs. 2012, 49, 5-19.
[171] Asif, M. Mini. Rev. Med. Chem. 2012, 12, 1404-1418.
[172] Asif, M.; Siddiqui, A.A.; Husain, A. Med. Chem. Res. 2013, 22, 1029-1042.
[173] Asif, M. Org. Chem: An Indian J. 2013, 9, 180-218.
[174] Lienhardt, C.; Raviglione, M.; Spigelman, M. J. Infect. Dis. 2012, 205, S241-S249.
[175] Lienhardt, C.; Vernon, A.; Raviglione, M.C. Curr. Opinion Pulmonary Med. 2010, 16, 186-193.
[176] Yadav, P.; Deolekar, P.; Kanase, V. IJPSR. 2012, 3, 2472-2481.
[177] Shehzad, A.; Rehman, G.; Ul-Islam, M. Braz. J. Infect. Dis. 2013, 17, 74-81.
[178] Anand, N.; Upadhyaya, K.; Tripathi, R.P. Chem.& Biol. Interface. 2015, 5, 84-127.
[179] Godebo, A.; Woldi, A.H.; Toma, A. Inter. J. Res. Pharm. Biosci. 2015, 2, 1-18.
[180] Kurbatova, E.V.; Cegielski, J.P.; Lienhardt, C. Lancet. Respir. Med. 2015, 3, 201-209.
[181] Zumla, A.I.; Schito, M.; Maeurer, M. Lancet. Infect. Dis. 2014, 14, 7-9.
[182] D’Ambrosio, L.; Centis, R.; Sotgiu, G.; Pontali, E.; Spanevello, A.; Migliori, G.B. ERJ. Open. Res. 2015, 1, 182.